Gonadotrophin Chorionicum (Human Chorionic Gonadotropin, HCG) veterinary-grade active pharmaceutical ingredient is a purified urine-derived glycoprotein hormone supplied under the model designations HCG-VET-API/2500 and HCG-VET-API/5000. These model codes correspond to nominal specific activities of 2500 IU/mg and 5000 IU/mg, respectively, calibrated against the WHO 5th International Standard for hCG (07/364). The molecule carries CAS registry number 9002-61-3 and has an approximate molecular mass of 36 700 Da. Structurally, HCG is a heterodimer assembled from an α subunit of 92 amino acids and a β subunit of 145 amino acids, with carbohydrate accounting for approximately 30% of total mass. The β subunit confers binding selectivity for the luteinizing hormone/choriogonadotropin receptor, producing LH-like activity. This receptor-level action distinguishes HCG from equine chorionic gonadotrophin/eCG, which exhibits both FSH-like and LH-like properties, and from synthetic GnRH analogues, which require intact pituitary gonadotrophin secretion. The product is not intended for human use; it is released as a white to off-white lyophilized or vacuum-dried powder for further pharmaceutical processing into tablets, injections, capsules, powders, granules, premixes, and solutions.

The bulk release specification is aligned with Ph. Eur. 0498 and the USP Chorionic Gonadotropin monograph where applicable. Residual moisture is determined by USP <921> Method Ic and controlled at ≤5.0% for powder grades, while sterile injection grades may require a dried-basis moisture target below 3.0% after lyophilization. Table 1 summarizes the core release framework.

Stability of the dry API is governed primarily by moisture ingress, thermal denaturation, and shear-induced aggregation. Unopened containers are stored at 2–8 °C with silica gel or molecular-sieve desiccant. Cumulative open-container exposure at relative humidity above 60% should be limited to 8 h unless in-process moisture mapping demonstrates acceptable activity retention. The powder is hygroscopic after lyophilization; repeated warming to ambient temperature should not exceed a cumulative 24 h without supporting stability data. Double lyophilization is not recommended because rehydration and refreezing stress can increase high-molecular-weight aggregates detectable by size-exclusion HPLC. Bulk packaging is typically a heat-sealed LDPE-lined aluminium foil pouch under nitrogen or argon headspace with residual oxygen below 2%, and the container-closure system is qualified under USP <671>.

Because HCG is a glycoprotein, the functional distinction from recombinant choriogonadotropin alfa and from urinary menotrophin preparations is analytically relevant. Recombinant HCG produced in Chinese hamster ovary cells carries different glycan branching, terminal sialylation, and core fucosylation; urinary HCG shows greater isoform heterogeneity. This heterogeneity does not usually alter receptor binding in a single bioassay but can shift in vivo clearance and apparent potency if the calibration standard is not matched to the assay system. Compared with eCG/PMSG, HCG has a shorter circulating half-life in cattle and horses but produces a more predictable LH-receptor drive, which is why HCG is used for ovulation induction rather than follicular recruitment. Batch-to-batch variance in isoform profile is controlled during purification by anion-exchange chromatography with conductivity-defined elution windows and by a final potency adjustment to the WHO International Standard.

What Limits Sterile Fill-Finish for Multi-Dose Injection Formats?

Aseptic filtration remains the only viable sterilization route for HCG injection solutions because terminal saturated steam exposure at 121 °C for 15 min produces irreversible subunit dissociation and precipitation. Compounding should be performed in an ISO 14644-1:2015 class 5 environment or equivalent EU GMP Annex 1 grade A zone, with airborne particles ≥0.5 µm controlled at 3 520 m−3 at rest. The bulk solution is passed through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane; maximum transmembrane pressure is held at 1.0 bar to limit shear aggregation. Filter integrity testing is performed before and after filtration by bubble point or forward-flow diffusion. Sterile filling is supported by process simulation with an acceptance criterion of less than 0.1% contaminated units, per FDA 21 CFR 211.165 and sterile manufacturing expectation.

For freeze-dried vials, the formulation typically contains mannitol or sucrose at 2–5% w/v as a lyoprotectant and cryoprotectant. Collapse temperature is determined by freeze-drying microscopy, and the lyophilization cycle is designed to maintain product temperature below the collapse value during primary drying. Residual moisture after opening the freeze-drying chamber is controlled at ≤3.0%. Multi-dose vial preparations require an antimicrobial preservative; benzyl alcohol at concentrations above 2.0% v/v is not recommended because of protein aggregation risk. Methylparaben and propylparaben combinations require glycoprotein compatibility validation by potency assay and subvisible particle counting. Container-closure integrity is verified on finished vials by dye ingress or helium leak methods. Product-contact surfaces should be 316L stainless steel or borosilicate glass; silicone tubing may adsorb HCG and should be avoided in long transfer lines unless a binding study demonstrates acceptable recovery.

For injection-path processing, the dissolution vessel is usually a jacketed 316L stainless-steel tank with low-shear agitation. Impeller tip speed is maintained below 3 m/s, and solution temperature during dissolution is held at 15–25 °C for no more than 4 h before filtration. In-process bioburden is sampled immediately before sterile filtration, with a typical action limit of 10 CFU/100 mL for the prefiltration bulk. The sterile filtrate is filled into depyrogenated glass vials; fill-volume checks are performed at intervals not exceeding 15 min. End-product testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, and potency by bioassay. Terminal vacuum drying is not a substitute for aseptic lyophilization when a sterile cake is required.

When HCG is destined for tablet or capsule intermediates, direct compression is rarely a first-line route because the low active content per unit dose requires extensive geometric dilution and the glycoprotein can be inactivated by high-energy milling. Roller compaction is preferred over high-shear wet granulation. Roller force is kept below 10 kN/cm, roll speed below 5 rpm, and ribbon density controlled at 0.8–1.1 g/cm³ to limit frictional heat. If wet granulation is unavoidable, the binder solution is cooled to 4–8 °C, and granulation end point is controlled by mixer power consumption rather than fixed impeller speed alone. Direct compression blends may use mannitol as a non-reducing diluent at 10–90% w/w depending on target potency; reducing sugars such as lactose monohydrate may be used only if forced degradation studies show no Maillard-type adduct formation. Capsule filling of HCG-containing granules is performed in humidity-controlled suites, preferably below 40% RH, because the API is hygroscopic and can adhere to stainless steel tooling.

Oral bioavailability of intact HCG in monogastric species is low because gastric pepsin and intestinal trypsin/chymotrypsin degrade the glycoprotein before absorption. Tablet and capsule presentations therefore serve primarily as stability-screening intermediates, local oral-mucosal research formulations, or non-sterile compounding formats rather than as systemic replacements for injection. Published in vivo pharmacokinetic data for veterinary oral HCG dosage forms is limited; bioequivalence to the injectable route should not be assumed without a controlled absorption study. For capsule shells, HPMC is generally preferred over hard gelatin when moisture transfer into the fill is a concern.

Powder, Granule and Premix Carrier Selection Criteria

Powder and granule presentation batches require a high-purity carrier system. Mannitol, lactose monohydrate, and corn cob granular carriers are selected according to final premix target and target-animal feeding behaviour. Geometric dilution in a V-blender or tumble mixer with a step ratio not exceeding 1+9 is the standard carrier dilution method. Fill volume is kept below 60% of rated blender capacity, and blend time is validated by assay uniformity at three time points, for example 3 min, 5 min, and 10 min. Final premix potency is confirmed by immunoassay or HPLC calibrated to the WHO hCG standard. Content uniformity acceptance is typically RSD ≤5.0% across sampling points.

Particle size of the API is controlled by laser diffraction, with a D90 below 100 µm for powder and granule intermediates. Premix carriers usually require a D50 of 150–500 µm to reduce segregation. Segregation risk increases with carrier particle size above 800 µm and with transport vibration; over-the-road simulated transport sampling is recommended before assigning a shelf life to finished premix. If the final premix target falls below 1000 IU g−1, the API is first triturated with 1 part API to 9 parts carrier, then diluted stepwise to target. Stainless steel blending equipment is passivated, and cleaning validation includes assay of final rinse water for residual HCG antigen and total organic carbon. Cross-contamination from other hormone APIs such as eCG and GnRH must be controlled by dedicated or validated-cleaned equipment because immunoassay cross-reactivity can mask carryover.

Extemporaneous aqueous solutions for veterinary administration are compounded as cold-process preparations. The powder is equilibrated to room temperature in a sealed container before opening to prevent condensation. Dissolution is carried out with slow orbital agitation rather than high-speed magnetic stirring to reduce air entrainment and shear. A 0.9% w/v sodium chloride vehicle or phosphate-buffered saline may be used; glucose-containing vehicles are avoided because of reducing-sugar adduct formation risk. Solutions without preservative should be used within 24 h when stored at 2–8 °C. Oil-based vehicles and emulsions should not be combined with HCG unless compatibility is demonstrated, because adsorption at the oil-water interface can denature the glycoprotein. Adsorption to polyvinyl chloride infusion bags and nylon filter membranes can occur; filter-binding studies are required before final solution manufacturing. The aqueous solution pH is maintained at 6.0–8.0; prolonged exposure outside this range accelerates subunit dissociation and loss of receptor-binding activity.

Differences from other gonadotropin products are operationally relevant. HCG acts directly on gonadal LH receptors and bypasses the pituitary, making it useful when pituitary responsiveness is downregulated or when a discrete LH surge is required. eCG/PMSG is generally used for follicular growth stimulation because of its combined FSH-like and LH-like activity and longer half-life. Synthetic GnRH analogues require functional pituitary gonadotrophs to release endogenous LH. Porcine FSH preparations are used for superovulation in cattle and sheep but do not provide the same luteinizing signal as HCG. The selection of HCG veterinary-grade API therefore depends on whether the intended protocol requires ovulation induction, luteal support, or direct luteinization. For sterile injection manufacture, the active ingredient is routinely supplied as a sterile-filtered and lyophilized powder; for powder, granule, and premix applications, a non-sterile bulk grade with equivalent potency standardisation is used. Each route has distinct stability, excipient compatibility, and regulatory documentation requirements.